TNFi plus csDMARD does not improve disease activity, HAQ in psoriatic arthritis
Tumour necrosis factor inhibitor (TNFi) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) does not appear to be any better than TNFi monotherapy at improving disease activity or Health Assessment Questionnaire (HAQ) in patients with psoriatic arthritis (PsA), reports a study. However, the combination therapy may improve TNFi survival.
TNFi plus csDMARD does not improve disease activity, HAQ in psoriatic arthritis
16 Jan 2021